Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

by Charlotte Charpentier, Catherine Fagard, Céline Colin, Christine Katlama, Jean-Michel Molina, Christine Jacomet, Benoit Visseaux, Anne-Marie Taburet, Françoise Brun-Vézinet, Geneviève Chêne, Yazdan Yazdanpanah, Diane Descamps, ANRS139 TRIO Trial study group
Published 2013-01-01